Leading the Way

in the fight to stop the most deadly cancer cells

By capturing the most deadly cells from a patient biopsy, we are leading the way to improve the care for cancer patients by providing personalized information to oncologists on which drugs can stop these deadly cells before treatment begins, and by discovering new cancer drugs specifically targeting these deadly cells responsible for metastasis, spread and recurrence.

Our patented, microfluidic phenotypic assay complements genomics and is the best cancer laboratory technology with unique device architecture and extracellular matrix environment that mimics what exists in the body. It is the only technology that is able to capture the most deadly cells. It is cost-effective and can deliver results quickly, within a couple of days.

© 2020 by RecurX Bio, Inc. All Rights Reserved in all countries. RecurX Bio is a trademark of RecurX Bio, Inc.